Other reasons why ADRC treatment did not affect AAA expansion could be (1) the time point of ADRCs delivery, (2) that a single injection of ADRCs was not enough to alter the progression of AAA, (3) the number of ADRCs was too low, or (4) ADRCs should have been further enriched by CD31+ selection, which is known to be responsible for enhancing the vascular regenerative potential of ADRCs in the treatment of erectile dysfunction, at least in human settings [18]. This evidence concerns the gene PECAM1 and triple-A syndrome.